Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

962 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients.
Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. Tawakol A, et al. Among authors: yates d. J Am Coll Cardiol. 2006 Nov 7;48(9):1818-24. doi: 10.1016/j.jacc.2006.05.076. Epub 2006 Oct 17. J Am Coll Cardiol. 2006. PMID: 17084256 Free article.
Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.
Choudhury RP, Birks JS, Mani V, Biasiolli L, Robson MD, L'Allier PL, Gingras MA, Alie N, McLaughlin MA, Basson CT, Schecter AD, Svensson EC, Zhang Y, Yates D, Tardif JC, Fayad ZA. Choudhury RP, et al. Among authors: yates d. J Am Coll Cardiol. 2016 Oct 18;68(16):1769-1780. doi: 10.1016/j.jacc.2016.07.768. J Am Coll Cardiol. 2016. PMID: 27737744 Free PMC article. Clinical Trial.
A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.
Russell KS, Yates DP, Kramer CM, Feller A, Mahling P, Colin L, Clough T, Wang T, LaPerna L, Patel A, Lawall H, Shennak MM, Fulmer J, Nikol S, Smith WB, Müller OJ, Ratchford EV, Basson CT. Russell KS, et al. Vasc Med. 2019 Oct;24(5):414-421. doi: 10.1177/1358863X19859072. Epub 2019 Jul 5. Vasc Med. 2019. PMID: 31277561 Free PMC article. Clinical Trial.
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.
von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T. von Stebut E, et al. Among authors: yates d. J Invest Dermatol. 2019 May;139(5):1054-1062. doi: 10.1016/j.jid.2018.10.042. Epub 2018 Nov 30. J Invest Dermatol. 2019. PMID: 30508547 Free article. Clinical Trial.
Coronary Artery Disease Polygenic Risk Score Identifies Patients at Higher Risk for Recurrent Cardiovascular Events in the CANTOS Trial.
Xu H, Hon C, Kaiser S, Serrano-Fernandez P, Hartmann N, Yates DP, Healey M, Gusev AI, Laramie JM, Kennedy S, Marc P, Ridker PM, Obeidat M, Beste MT, Svensson EC, Madar A. Xu H, et al. Circ Genom Precis Med. 2021 Dec;14(6):e003440. doi: 10.1161/CIRCGEN.121.003440. Epub 2021 Oct 19. Circ Genom Precis Med. 2021. PMID: 34663088 No abstract available.
Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
Corcoran D, Radjenovic A, Mordi IR, Nazir SA, Wilson SJ, Hinder M, Yates DP, Machineni S, Alcantara J, Prescott MF, Gugliotta B, Pang Y, Tzemos N, Semple SI, Newby DE, McCann GP, Squire I, Berry C. Corcoran D, et al. Among authors: yates dp. Cardiovasc Res. 2021 Jan 1;117(1):320-329. doi: 10.1093/cvr/cvz345. Cardiovasc Res. 2021. PMID: 32065620 Free PMC article. Clinical Trial.
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, Hrabak-Paar M, Heye T, Aichner S, Khder Y, Yates D, Albrecht D, Langenickel T, Freyhardt P, Janka R, Bremerich J. Schmieder RE, et al. Among authors: yates d. Eur Heart J. 2017 Nov 21;38(44):3308-3317. doi: 10.1093/eurheartj/ehx525. Eur Heart J. 2017. PMID: 29029087 Clinical Trial.
Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.
Snowdon VK, Lachlan NJ, Hoy AM, Hadoke PW, Semple SI, Patel D, Mungall W, Kendall TJ, Thomson A, Lennen RJ, Jansen MA, Moran CM, Pellicoro A, Ramachandran P, Shaw I, Aucott RL, Severin T, Saini R, Pak J, Yates D, Dongre N, Duffield JS, Webb DJ, Iredale JP, Hayes PC, Fallowfield JA. Snowdon VK, et al. Among authors: yates d. PLoS Med. 2017 Feb 28;14(2):e1002248. doi: 10.1371/journal.pmed.1002248. eCollection 2017 Feb. PLoS Med. 2017. PMID: 28245243 Free PMC article. Clinical Trial.
962 results